EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Mycobacterium bovis Infections Following Intravesical Bacillus Calmette-Guérin Instillation for Bladder Cancer in Western Australia: A 22-Year Retrospective Review

Usha Manickavasagar iD, Henco Nel iD, Jason Seet, Liana Varrone iD, Terillee Keehner, Rebecca McCann, Rosie Barnes, Angela Jacques iD, Penelope Clohessy

Open Forum Infectious Diseases · 31.01.2025 · 12 (2)

DOI: 10.1093/ofid/ofaf070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 07.02.2025. Verfasst von Usha Manickavasagar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Sir Charles Gairdner Hospital, Perth, Australia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycobacterium bovis bacillus Calmette-Guérin (BCG) infection following intravesical BCG instillation is a rare complication of therapy that is associated with significant morbidity and mortality. We conducted a multicenter retrospective review of microbiologically confirmed M.bovis BCG infections in Western Australia over 22 years. Thirty-three patients were included in our study. All patients were male with a median age of 72 years. Localized infections accounted for 22/33 cases while disseminated infections accounted for 11/33 cases. The majority (n = 21) of positive isolates were cultured from urine specimens, followed by tissue and blood. The median time between first BCG instillation and infection was 7.5 months (95% CI, 3.5–11.5). The median duration of antimycobacterial therapy for localized infections was 6 months (95% CI, 4.1–7.9) as compared with 9 months (95% CI, 7.9–10.1) for disseminated infections (P = .039). The attributed mortality was 14.3%. M.bovis BCG infections have diverse clinical presentations and clinicians must have a high index of suspicion when assessing patients with a history of intravesical BCG instillation.

Schlagwörter

Stichwörter der Autor:innen

Mycobacterium bovisbacillus Calmette-Guérin, BCGbladder cancerinfectionsintravesical

Autor:innen und Institutionen

  • Department of Infectious Diseases, Sir Charles Gairdner Hospital, Perth, Australia.
  • University of Western Australia, Perth, Australia.
  • Western Australian Department of Health, Perth, Australia.
  • Mycobacterium Reference Laboratory, PathWest, Queen Elizabeth II Medical Centre, Perth, Australia.
  • Institute of Health Research, The University of Notre Dame, Perth, Australia.

ORCID-Profile: Usha Manickavasagar, Henco Nel, Liana Varrone, Angela Jacques

Zitieren

APA

Manickavasagar, U., Nel, H., Seet, J., Varrone, L., Keehner, T., McCann, R., Barnes, R., Jacques, A., & Clohessy, P. (2025). Mycobacterium bovis Infections Following Intravesical Bacillus Calmette-Guérin Instillation for Bladder Cancer in Western Australia: A 22-Year Retrospective Review. Open Forum Infectious Diseases, 12(2). https://doi.org/10.1093/ofid/ofaf070

Vancouver

Manickavasagar U, Nel H, Seet J, Varrone L, Keehner T, McCann R, et al. Mycobacterium bovis Infections Following Intravesical Bacillus Calmette-Guérin Instillation for Bladder Cancer in Western Australia: A 22-Year Retrospective Review. Open Forum Infectious Diseases. 2025;12(2). doi:10.1093/ofid/ofaf070

BibTeX
@article{Manickavasagar2025,
  author = {Manickavasagar, Usha and Nel, Henco and Seet, Jason and Varrone, Liana and Keehner, Terillee and McCann, Rebecca and Barnes, Rosie and Jacques, Angela and Clohessy, Penelope},
  title = {Mycobacterium bovis Infections Following Intravesical Bacillus Calmette-Guérin Instillation for Bladder Cancer in Western Australia: A 22-Year Retrospective Review},
  journal = {Open Forum Infectious Diseases},
  year = {2025},
  volume = {12},
  number = {2},
  doi = {10.1093/ofid/ofaf070}
}
Kostenlos starten →